Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.31 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 2/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PTPRC | P08575 | 1/20 | 0.30 |
| ▸ | PTPRF | P10586 | 1/20 | 0.30 |
| ▸ | PTPRA | P18433 | 1/20 | 0.30 |
| ▸ | PTPRB | P23467 | 1/20 | 0.30 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18926672 | 0.81 | PTPN1 (0.36) | PTPN1CDK4CCND1MAP3K9MAP3K11 | |
| SCHEMBL18927272 | 0.79 | PDK2 (0.33) | ALOX5 | |
| SCHEMBL4554429 | 0.79 | KDM4E (0.36) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL22054389 | 0.76 | TNKS (0.31) | TNKSTNKS2 | |
| SCHEMBL18926774 | 0.75 | TNKS (0.35) | GPR3MAPTALDH1A1HPGDPTPN1 | |
| SCHEMBL18926646 | 0.73 | PTPN1 (0.32) | PTPN1CDK4CCND1MAP3K9MAP3K11 | |
| SCHEMBL18926896 | 0.72 | NQO1 (0.34) | — | |
| SCHEMBL16614139 | 0.72 | KDM4E (0.34) | GPR3MAPTRAB9ASMN1; SMN2ALOX5 | |
| SCHEMBL24279246 | 0.71 | ALOX5 (0.34) | MAPTSMN1; SMN2ALOX5 | |
| SCHEMBL18731812 | 0.71 | ALOX5 (0.36) | GPR3MAPTALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11683980-B2 | Condensed fluorene derivative comprising heterocyclic ring | SFC CO., LTD. (KR) | 2023-06-20 | — | — | US | disclosed |
| US-11683980-B2 | Condensed fluorene derivative comprising heterocyclic ring | SFC CO., LTD. (KR) | 2023-06-20 | — | — | US | disclosed |
| EP-4116297-A1 | CONDENSED FLUORENE DERIVATIVE COMPRISING HETEROCYCLIC RING | SFC Co., Ltd. (KR) | 2023-01-11 | — | — | EP | disclosed |
| US-20170222155-A1 | CONDENSED FLUORENE DERIVATIVE COMPRISING HETEROCYCLIC RING | SFC CO., LTD. (KR) | 2017-08-03 | — | — | US | disclosed |
| US-20170222155-A1 | CONDENSED FLUORENE DERIVATIVE COMPRISING HETEROCYCLIC RING | SFC CO., LTD. (KR) | 2017-08-03 | — | — | US | disclosed |
| EP-3176158-A2 | CONDENSED FLUORENE DERIVATIVE COMPRISING HETERO RING | SFC Co., Ltd. (KR) | 2017-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170222155-A1 | CONDENSED FLUORENE DERIVATIVE COMPRISING HETEROCYCLIC RING | CCNE2, INF2, AFF4 | GPR3 2083/4885MAPT 2034/4885ALDH1A1 2192/4885 |
| US-11683980-B2 | Condensed fluorene derivative comprising heterocyclic ring | CCNE2, INF2, AFF4 | GPR3 2083/4885MAPT 2034/4885ALDH1A1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.